Date: August 8, 2026
Regulatory Update
Emcure Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) regarding the inspection conducted at the Company's formulations facility located at G.I.D.C., Taluka - Sanand, Ahmedabad – 382110, Gujarat.
The inspection was conducted from May 06, 2026 to May 15, 2026, as previously intimated to the exchanges on May 16, 2026.
The USFDA has classified the inspection status of the Sanand facility as Voluntary Action Indicated (VAI).
With this classification, the inspection stands officially closed.